Commercial Partnerships
Cancer Research UK’s Commercial Partnerships team, formerly known as Cancer Research Technology (CRT), develop and commercialise exciting new discoveries in cancer research. Our deep understanding of both academia and industry enables us to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return.
Exclusive rights to over £350m of cancer research per year
Our marketed drugs include Temodal, Zytiga, Erivedge, Lynparza and Rubraca.
We speak your language
Cancer Research UK's Commercial Partnerships team translates academic research into industry propositions.
£29m in grants and support leveraged last year
If a project looks promising, we’ll find a way to move it forward.
Realising clinical and commercial potential
We’re driven to achieve maximum patient benefit and market value.
Many projects, one focus: cancer
Our specialism means we’re more experienced, more knowledgeable and better connected.
CRUK Therapeutic Discovery Laboratories principal focus is on establishing and prosecuting biologically-themed multi-project alliances with industry to deliver breakthrough medicines for cancer patients.
With exclusive rights to more than £350m of world-class cancer research a year, we’re the gateway to much of the high quality oncology research happening in the UK today.
Do you have an idea or a discovery with commercial potential? Are you interested in working with industry? Our team can help develop the most promising projects.
| Start Date | Event |
|---|---|
| 01 April 2017 | AACR Annual Meeting 2017 |
| 19 March 2017 | Bio-Europe Spring 2017 |
| 29 November 2016 | 28th EORTC-NCI-AACR Symposium |
| 07 November 2016 | Bio-Europe Autumn 2016 |
| 06 November 2016 | NCRI Cancer Conference 2016 |
We've established major partnerships with research institutions, pharmas and biotechs of all sizes.
